Erasca ERAS 深 滬
等待開盤 08-21 09:30:00 美东时间
17.08
-0.990
-5.48%
華盛通- 最 高17.77
- 今 開17.59
- 成交量 266.64万股
- 最 低 16.92
- 昨 收 18.07
- 總市值 59.74亿
- 52周最高 24.28
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 1.3301
- 委 比 -92.53%
- 總股本 3.50亿
- 歷史最高 24.47
- 量 比 1.06
- 振 幅 4.70%
- 歷史最低 1.01
- 每 手 1
- 風險率 6.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $18 to $22.
08-12 18:18
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year.
08-12 04:39
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
Erasca reported positive updated clinical data for ERAS-0015 in 2L+ KRAS G12X pancreatic and lung cancers, with a 57% objective response rate and favorable tolerability. The company secured $632 million in financing, strengthening its balance sheet to $384 million. Key upcoming milestones include Phase 1 data in H1 2027 and potential registration-enabling trials for pancreatic and lung cancers.
08-11 20:01
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Erasca, Inc. announced the grant of inducement awards to Dr. Charles S. Fuchs upon his appointment as President of Research and Development. The Board of Directors approved non-qualified stock options for Dr. Fuchs to purchase 1,278,520 shares under the 2026 Inducement Plan. 25% vests on August 10, 2027, with the remainder vesting in 36 monthly installments. The options were granted on August 10, 2026, with an exercise price equal to the closing ...
08-10 20:01
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
7月17日隔夜要闻：美股收跌科技股领跌 油价下跌 镍价上涨 金价走低 白宫称伊朗仍在与美国对话
专题：AI景气度仍向好 市场正进入结构性分化新阶段 市场 7月17日收盘：美股收跌科技股领跌，芯片股再遭抛售 7月17日热...
07-17 05:41
